Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2327553 | 0.82 | KLKB1 (0.31) | KLKB1 | |
| SCHEMBL2328383 | 0.80 | KDM4E (0.41) | KLKB1KDM4ETDP1LMNAHIF1A | |
| SCHEMBL3721159 | 0.77 | KLKB1 (0.34) | KLKB1KDM4ETDP1 | |
| SCHEMBL2327516 | 0.75 | KMT2A (0.33) | LMNA | |
| SCHEMBL2329158 | 0.72 | KLKB1 (0.34) | KLKB1 | |
| SCHEMBL2819279 | 0.72 | HIF1A (0.31) | TDP1HIF1AEPAS1 | |
| SCHEMBL2327771 | 0.70 | KLKB1 (0.34) | KLKB1LMNA | |
| SCHEMBL3657220 | 0.70 | KLKB1 (0.33) | KLKB1 | |
| SCHEMBL1167800 | 0.69 | LMNA (0.41) | KLKB1LMNA | |
| SCHEMBL2644219 | 0.68 | ADORA3 (0.34) | KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536209-B2 | Aminotriazole derivatives as ALX agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-17 | — | — | US | claimed |
| EP-2225231-B1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | claimed |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION (CH) | 2010-12-30 | — | — | US | claimed |
| US-8536209-B2 | Aminotriazole derivatives as ALX agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION (CH) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ADORA1, ADORA3, TBXA2R | KLKB1 4485/4885KDM4E 1611/4885TDP1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.